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Abstract: Merkel cell carcinoma (MCC) is an aggressive, virus-associated, neuroendocrine tumor of the skin mainly 
affecting immunocompromised patients. Higher intratumoral infiltration with CD3 and CD8 positive T-cells is associ-
ated with a better prognosis, highlighting the relevance of the immune system for MCC development and progres-
sion. In this study 21 primary MCCs were stained with immune cell markers including CD3, CD4, CD8, CD68, CD20, 
and S100. Furthermore, tumor-infiltrating neutrophils, tertiary lymphoid structures and PD-L1 expression were ana-
lyzed and correlated with overall and recurrence free survival. All MCCs were Merkel Cell Polyomavirus positive. 
Overall and recurrence-free survival did not correlate with intra- and peritumoral CD3 and CD8 T-cell infiltration. In 
addition, no significant association regarding prognosis was found for tumor-associated neutrophils, tumor-associat-
ed macrophages or PD-L1 positivity in MCCs. Interestingly, the presence of tertiary lymphoid structures (TLS) in the 
tumor microenvironment significantly correlated with recurrence-free survival (P=0.025). In addition, TLS were sig-
nificantly associated with a higher CD8/CD4 ratio in the tumor periphery (P=0.032), but not in the center of the tu-
mor (P > 0.999). These results demonstrate for the first time that TLS, easily assessed in paraffin-embedded tissue 
in the tumor periphery of MCCs, may be a valuable prognostic factor indicating prolonged recurrence free survival.
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Introduction
Merkel cell carcinomas (MCCs) are rare and 
highly aggressive neuroendocrine neoplasms 
of the skin that mainly develop in elderly or 
immunocompromised patients [1]. The associ-
ation between MCC development and immuno-
suppression led to the groundbreaking idea 
that MCC might belong to oncovirus-induced 
cancers. In 2008, Feng et al. described for the 
first time Merkel Cell Polyomavirus (MCPyV) in 
8 out of 10 MCCs [2]. Most MCPyV-positive 
MCCs express several MCPyV proteins, among 
them large T antigen and small T antigen which 
potentially stimulate tumor cell proliferation. 
This and other observations support a patho-
genic role of MCPyV for MCC development 
[3-7]. Dependent on the detection method 
used, MCPyV is found in about 80-100% of 
MCCs [8]. It is still unclear whether in negative 
MCCs the detection method was not sensitive 
enough or whether such MCCs have another 
etiology or loose MCPyV oncogene expression 
during tumor progression [9].
Several lines of evidence support the notion 
that a strong immune response correlates with 
better outcome in patients with MCC. A gene 
expression analysis comparing mRNA of MCCs 
from patients with good and poor prognosis 
showed a prominent immune response gene 
signature in those with a good prognosis [10]. In 
particular, up-regulation of CD8a and gran-
zymes were associated with better outcome, 
which points to a central role of CD8 lympho-
cytes for a successful anti-tumor immune 
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response. No association with M2 macrophage 
infiltration characterized by CD68/CD163 posi-
tivity was found [11]. It has not been studied so 
far whether other innate immune cells such as 
myeloid-derived suppressor cells or tumor-as- 
sociated neutrophils (TANs) are implicated in 
MCC progression, but their tumor promoting 
properties have been shown for many other 
tumor entities [12, 13].
Additional histopathological features previously 
associated with a better prognosis of patients 
with different kinds of tumors are tertiary lym-
phoid structures (TLS) present in the tumor 
environment [14-16]. Tertiary lymphoid struc-
tures (TLS) are known to play an important role 
in autoimmunity, organ transplantation and 
infection. They constitute important ectopic an- 
tigen-presenting formations with structural si- 
milarities to lymph nodes. Infiltrating CD20-
positive B cells cluster with T cells and dendritic 
cells and form germinal center-like patterns 
that lead to the development of specific humor-
al and cell-mediated immune responses, there-
by sustaining long-term immunity [17]. Recent 
studies have identified TLS in the tumor micro-
environment as a site of dendritic cell (DC), B 
cell and T cell priming and maturation with a 
resultant stronger anti-tumor immune response 
and longer overall survival [18-20]. However, 
the presence of TLS and their significance for 
overall and recurrence-free survival has so far 
not been studied in MCC.
Evidence that the immune system significantly 
contributes to MCC development and progres-
receptor PD-1. In addition, PD-L1 expression 
has been described in MCCs, tumor-infiltrating 
and peritumoral leucocytes [23, 24]. These 
findings imply the possibility that blocking anti-
bodies against PD-1 or PD-L1 could enhance 
an endogenous anti-tumor response leading to 
tumor regression. 
In the present study we investigated the corre-
lation of intratumoral and peritumoral CD3+ 
lymphocytes, CD8+ cytotoxic cells, CD4+ T-hel- 
per cells, CD68+ macrophages, and tumor-
associated neutrophils with overall and recur-
rence-free survival in 21 patients with primary 
MCC. In addition, we examined whether PD-L1 
expression in MCC and the presence of tertiary 
lymphoid structures in the tumor microenviron-
ment was associated with a better prognosis.
Materials and methods
Patients and tumor tissues
Our sample comprised 43 formalin-fixed paraf-
fin-embedded Merkel cell carcinoma (MCC) 
specimens from 34 patients, which had been 
surgically removed or biopsied between 1997 
and 2013 at the University Hospital Mannheim, 
University of Heidelberg, Germany (n=37 tu- 
mors from 31 patients) or at the Department of 
Dermatology of the University Hospital Giessen, 
Germany (n=6 tumors from 3 patients). Out of 
the 34 subjects 7 were excluded due to incom-
plete clinical data, insufficient amounts of par-
affin-embedded MCC tissue or inadequate tis-
sue sample quality. The final study cohort con-
Figure 1. Flowchart of subjects included in the study.
sion implies that novel thera-
peutic options for MCC sh- 
ould support the develop-
ment of an anti-tumor direct-
ed immune response. It has 
already been revealed in pa- 
tients with advanced mela-
noma that such therapies 
can be effective [21]. Immune 
checkpoint blockade with th- 
erapeutic antibodies target-
ing CTLA-4, PD-1 and its li- 
gand PD-L1 leads to durable 
objective tumor response in 
up to one third of melanoma 
patients [22]. Recently, MCP- 
yV-specific CD8+ T-cells have 
been identified in the blood 
of patients with MCC [23]. 
These T-cells expressed high-
er levels of the coinhibitory 
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tained material of 21 primary carcinomas from 
21 subjects as well as 3 local recurrences and 
3 metastases from 6 subjects (Figure 1). All 
tumors were positive for the Merkel cell marker 
cytokeratin 20.
Clinical data including age, sex, immune status, 
localization and kind of MCC, stage at initial 
diagnosis and at the end of follow-up period, 
recurrence, recurrence-free and overall survival 
were extracted from the patients’ clinical re- 
cords. Immunosuppression was assumed in 
patients with inherited or acquired immunodefi-
ciency syndromes, organ transplant, other dis-
seminated malignancies, immunosuppressive 
medications or chemotherapy. Staging was per- 
formed according to the classification suggest-
ed by the American Joint Cancer Committee 
(AJCC) in 2010 [25]. Due to the fact that the 
size of the primary MCC was only inconsistently 
reported, patients were categorized into local-
ized disease (stages I and II), regional disease 
(stage III) and disseminated disease (stage IV). 
Local recurrences were classified as stage II, 
lymph node metastases and in-transit metas-
tases as stage III. For patients presenting a pri-
mary MCC at initial contact, recurrence-free 
survival was defined as the disease-free inter-
val between curative treatment of the primary 
tumor and if applicable concomitant metasta-
ses, and relapse of the MCC in months. If 
patients initially presented local recurrences or 
MCC metastases, recurrence-free survival was 
defined as the disease-free interval after cura-
tive treatment of the recurrence or the metas-
tases. If patients experienced several relapses 
in the course of their disease, time until the first 
relapse was taken into account. Patients who 
never reached a disease-free state were de- 
fined as having a recurrence-free survival of 0 
months. All procedures were performed accord-
ing to the principles of the Declaration of He- 
lsinki and approved by the local medical ethic 
committee.
Immunohistochemistry and light microscopy
One µm-sections of paraffin-embedded MCC 
tissues were dried at 37°C overnight and depa-
raffinized using graded alcohol series accord-
ing to standard protocols. Subsequent heat-in- 
duced antigen retrieval was carried out in either 
Heat-Induced Epitope Retrieval (HIER) citrate 
buffer (pH6) for 40 min at 95°C or Tris/EDTA 
buffer pH9 (Leica Biosystems, UK, Novocastra 
Epitope Retrieval Solutions) for 20 min at 95°C 
using a water bath. All MCCs were stained with 
antibodies against the marker protein cytokera-
tin 20 (Clone Ks 20.8, Dako M7019, Hamburg, 
Germany) at a working concentration of 0.25 
µg/mL. The percentage of proliferating cells 
was determined by staining with Ki67 antibody 
(Ab15580, Abcam, Cambridge, UK) at a con-
centration of 3 µg/mL. For evaluation of tumor 
stroma cells the following antibodies were used 
for staining: Stabilin-1 (custom-made rabbit 
anti-mouse/human stabilin-1 antibody (RS1), 
PSL GmbH, Heidelberg, Germany; working dilu-
tion 1:1000), CD68 (Clone PG-M1, Dako M0- 
876; 0.1 µg/mL), CD163 (PHA-69786, Dianova, 
Hamburg, Germany; working dilution 1:100), 
CD3 (Clone SP7, RM-9107 Thermo Scientific, 
Ulm, Germany 1:150); CD4 (NCL-CD4-1F6, 
Novocastra, Wetzlar, Germany; 80 µg/mL); CD8 
(Clone 8/144B, Dako M7103, 3 µg/mL), CD31 
(Clone JC70A, Dako M0823, 1:100), PD-1 (Ab- 
52587, Abcam, Cambridge, UK; 20 µg/mL) and 
PD-L1 (anti human B7-H1 clone 5H1, 2 µg/mL, 
kindly provided by Dr Lieping Chen, Yale Cancer 
Center, New Haven, USA [26]), CD20 (Clone 
L26, Dako M0755, working dilution 1:1500), 
and S100 (Dako Z0311, 1:100). Antigen-bound 
primary antibodies were visualized by appropri-
ate horseradish-peroxidase (HRP)-coupled sec-
ondary antibodies, HRP-coupled polymers or 
Avidin-Biotin Complex (ABC) in combination 
with Streptavidin-HRP (PD-L1). AEC Substrate-
Chromogen (Dako) was precipitated by HRP-
activation, followed by hematoxylin counters- 
tain. 
Images of all stained tumor slides were record-
ed with a Nikon Eclipse Ni-E microscope (Nikon 
DS-U3 Digital Camera Control Unit) and soft-
ware system (Nikon, Düsseldorf, Germany). The 
absolute number of positively stained intratu-
moral cells was counted using ImageJ count in 
an area of 1 mm2.
Scoring
Absolute cell counts were assessed for intratu-
morally-localized cells positive for CD3, CD4, 
CD8, CD68 cells, for CD31-positive vessels and 
for PD-L1-positive macrophages. TAN infiltra-
tion in the tumor was HE-morphologically evalu-
ated and grouped into two categories (I: < 5%, 
II: > 5%). The percentage of positive cells com-
pared to the total peritumoral immune cell infil-
tration was determined for peritumoral CD4, 
CD8, CD68 cells and TANs and accordingly 
grouped into categories (I: < 10%; II: 10-50%; 
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III: > 50%). CD8/CD4 ratio was assessed in the 
tumor center and periphery and was then 
dichotomized for statistical analysis (CD8/ 
CD4 ≤ 1 or > 1). TLS were identified by HE- 
morphological appearance and staining with 
CD4, CD8, CD20 and S100 antibodies (Figure 
2B-E).
Membranous PD-L1 expression in MCCs was 
dichotomized into two categories (absent or low 
vs. strong). More than 50 PD-L1-positive intra-
tumoral macrophages/mm2 were classified as 
strong infiltration, ≤ 50 as a limited infiltration. 
The extent of PD-L1 expression in peritumoral 
lymphohistiocytic infiltrates was classified into 
the categories limited (≤ 10%) or strong (> 
10%). 
Evaluation and counting was performed by two 
independent investigators (D.S.B. and A.S.). In 
case of discordance a third investigator (W.K.P.) 
was consulted and specimens were discussed 
until unanimous agreement was achieved.
DNA isolation and Merkel cell polyomavirus 
detection
DNA was isolated from serial paraffin sections 
using a DNA Isolation Kit (Qiagen, Hilden, 
Germany). MCC samples were analyzed for the 
presence of MCPyV by using a TaqMan assay 
specific for the MCPyV large T antigen and VP1 
gene, as described previously [27, 28].
Statistical analysis
Statistical analysis was performed with the 
Statistical Package for Social Science (IBM 
Corp. Released 2012. IBM SPSS Statistics for 
Mac, Version 21.0. Armonk, NY: IBM Corp.). Ma- 
nn-Whitney-U tests or Student T-tests were 
applied for continuous distributions and Fi- 
sher’s Exact-Tests for categorical distributions. 
Spearman’s P was used for correlations with 
non-normal distribution. All statistical tests 
were two-sided, and a P-value ≤ 0.05 was con-
sidered as significant.
Results
Impact of tumor infiltrating leukocytes on over-
all and recurrence-free survival
In our patient cohort the mean age at first diag-
nosis of MCC was 71.9 years and 11.1% of the 
patients were immunosuppressed (Table 1). 
The most frequent localization of the primary 
tumor was the head and neck region (48.1%). 
At initial diagnosis, 74.1% of the patients had 
localized disease (stage I or II according to the 
classification suggested by the AJCC 2010). At 
the end of the follow-up period 48.1% still had 
Figure 2. TLS as prognostic markers in MCCs. (A) Box blot showing the association between TLS and recurrence-free 
survival (p=0.25, Mann-Whitney-U-Test); (B) Immunohistochemical staining of TLS with anti-CD4 antibody; (C-E) Im-
munohistochemical stainings with antibodies against CD8 (C), CD20 (D), and S100 (E) visualizing TLS. Scale bar: 
100 μm.
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local disease while 14.8% suffered from region-
al disease and 25.9% from distant metastases. 
Local recurrence occurred in 25.9%. In the 
whole patient sample, the mean recurrence-
free survival was 19.7 months and the mean 
overall survival 42.5 months. Patients with pri-
mary MCCs had a mean recurrence-free sur-
vival of 24.4 months and a mean overall sur-
vival of 39.2 months. All MCCs were MCPyV-
positive (Table 1).
0.457, P=0.075) or overall survival (CD31: 
Spearman’s ρ=-0.123, P=0.627, Ki67: Spe- 
arman’s ρ=0.08, P=0.752).
Correlation of tumor-associated neutrophils, 
tertiary lymphoid structures and PD-L1 with 
survival
Recent studies point to a negative correlation 
of tumor-associated neutrophil (TAN) infiltration 
with tumor prognosis [12] and to a favorable 
Table 1. Characteristics of the study cohort
All MCCs 
(n=27)
Primary 
MCCs (n=21)
Age (y), mean (SD) 71.9 (12.7) 71.5 (12.3)
Female, n (%) 15 (55.6) 10 (47.6)
Immunosuppression, n (%)* 3 (11.1) 3 (14.3)
Diabetes Mellitus, n (%) 5 (18.5) 3 (14.3)
Localization of primary tumor, n (%)
    Head and Neck 13 (48.1) 9 (42.9)
    Upper extremities 3 (11.1) 2 (9.5)
    Trunk 5 (18.5) 4 (19.0)
    Lower extremities 6 (22.2) 6 (28.6)
Stage at initial diagnosis, n (%)
    Localized disease (stage I/II) 20 (74.1) 15 (71.4)
    Regional disease (stage III) 5 (18.5) 4 (19.0)
    Disseminated disease (stage IV) 1 (3.7) 1 (4.8)
    Missing 1 (3.7) 1 (4.8)
Stage at end of follow up, n (%)
    Localized disease (stage I/II) 13 (48.1) 12 (57.1)
    Regional disease (stage III) 4 (14.8) 3 (14.3)
    Disseminated disease (stage IV) 7 (25.9) 4 (19.0)
    Missing 3 (11.1) 2 (9.5)
Recurrence, n (%)
    Yes 7 (25.9) 5 (23.8)
    Unknown 7 (25.9) 4 (19.0)
Follow-Up
    Available, n (%) 25 92.6 19 90.5
    Duration (months), mean (SD) 21.2 (28.5) 22.1 (32.2)
Survival
    Recurrence-free (months, n=22), mean (SD) 19.7 (27.1) 24.4 (30.5)
    Overall (months, n=24), mean (SD) 42.5 (40.1) 39.2 (39.5)
Treatment, n (%)
    Surgery 25 (92.6) 19 (90.5)
    Radiationtherapy 13 (48.1) 8 (38.1)
    Chemotherapy 3 (11.1) 1 (4.8)
Merkel Cell Polyomavirus, n (%) 27 (100) 21 (100)
SD: standard deviation; *The three immunocompromised patients suffered from my-
cosis fungoides or from non-Hodgkin lymphoma or received an immunosuppressive 
therapy for rheumatoid arthritis (leflunomid and prednisolone).
Since it has been suggested 
that a high intratumoral T-cell 
(CD3+) and cytotoxic T-cell 
(CD8+) count is associated 
with a favorable prognosis of 
MCC patients [10, 29], we 
assessed the composition of 
the inflammatory infiltrate in 
the 21 primary MCCs of our 
cohort and its correlation with 
recurrence-free and overall 
survival. Exemplary immuno-
histochemical stainings are 
shown in Supplementary Fi- 
gure S1, and raw data of CD3, 
CD4, CD8, CD68, CD31 and 
ki67 cell counts in Supp-
lementary Table S1. PD-1 pos-
itive T-cells were scares and 
only found in the stroma of 4 
out of 21 MCCs. Nearly all 
macrophages present in the 
MCCs stained positive for 
CD163. Interestingly, no Stabi- 
lin-1+ macrophages were de- 
tected in the MCCs, only the 
surrounding tissue macroph- 
ages expressed Stabilin-1. No- 
ne of the leukocyte antigens 
examined (CD3, CD4, CD8, 
CD8/CD4 ratio, CD68) were 
significantly associated with 
overall survival or recurrence-
free survival when counted 
intratumorally (Table 2) or in 
the tumor periphery (data not 
shown). Furthermore, the in- 
tratumoral density of CD31+ 
vessel and the proliferation 
rate assessed by Ki67 sta- 
ining did not correlate with 
recurrence-free survival (CD- 
31: Spearman’s ρ=-0.037, P= 
0.892, ki67: Spearman’s ρ= 
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prognosis when tertiary lymphoid structures 
(TLS) are found in the tumor periphery [17-19] 
or when MCCs are PD-L1 positive [24].
In our cohort of 21 patients with primary MCCs, 
neither a significant association of overall sur-
vival with intratumoral (TAN+ vs. TAN-: median 6 
months (IQR 5, 80.5) (n=4) vs. median 34.5 
months (IQR 13.75, 58.25), n=14, P=0.524) or 
with peritumoral (TAN+ vs. TAN-: median 5 mo- 
nths (IQR n.a.) (n=2) vs. median 3.5 months 
(IQR 9.5, 58.75) (n=16), P=0.16) TAN infiltra-
tion, nor an association of recurrence-free sur-
vival with intratumoral (TAN+ vs. TAN-: median 3 
initial diagnosis did not correlate with the pres-
ence of TLS (Table 3).
TLS have also been described in metastatic 
tumors including metastatic melanomas [30, 
31]. We therefore analyzed if TLS were present 
also in local recurrences and in metastases. 
Indeed, all local recurrences and all metasta-
ses contained TLS.
PD-L1 expression by MCCs has been shown to 
correlate with improved overall survival of 
patients with MCC [24]. We therefore analyzed 
whether PD-L1 expression in tumor cells, intra-
Table 2. Correlation of intratumoral immune markers with overall and 
recurrence-free survival
Overall survival Recurrence-free survival
N Spearman’s ρ P-value N Spearman’s ρ P-value
CD3 17 0.156 0.55 15 -0.271 0.329
CD4 17 -0.296 0.248 15 -0.355 0.194
CD8 18 0.07 0.783 16 -0.194 0.472
CD4/CD8 17 -0.25 0.333 15 0.002 0.995
CD68 18  0.152 0.548 16 -0.323 0.222
CD31 18 -0.123 0.627 16 -0.037 0.892
Ki67 18 0.08 0.752 16  0.457 0.075
Table 3. Associations between tertiary lymphoid structures (TLS) and 
clinicopathological or prognostic features
TLS+ TLS- P
n 8 13
Age (y), mean (SD) 66.9 (13.4) 74.3 (11.3) 0.209*
Sex
    Female (n=10), n (%) 4 (50) 6 (46.2) > 0.999†
    Male (n=11), n (%) 4 (50) 7 (53.8)
Stage initial diagnosis, n (%)
    I/II 5 (62.5) 10 (76.9) > 0.999†
    III/IV 2 (25.0) 3 (23.1)
    Unknown 1 (12.5) 0 (0)
Local, n (%)
    Yes 1 (12.5) 4 (30.8) 0.338†
    No 6 (75) 6 (46.2)
    Unknown 1 (12.5) 3 (23.1)
Recurrence-free survival (month, n=16)
    Median (IQR 25, 75) 40 (15, 70.5) 3 (0.75, 22.75) 0.025*
    Min-Max 3-105 0-57
Overall survival (month, n=18)
    Median (IQR 25, 75) 29 (5; 59) 18 (5; 57) 0.651*
    Min-Max 2-105 1-135
SD: standard deviation; *Mann-Whitney-U-Test; †Fisher’s Exact Test.
months (IQR n.a.) (n=3) 
vs. median 17.0 months 
(IQR 1, 45.5), n=13, P= 
0.635) or peritumoral 
(TAN+ vs. TAN-: median 3 
months (IQR n. a.) (n=2) 
vs. median 18 months 
(IQR 1, 52.5) (n=14), P= 
0.522) TAN infiltration 
was found, although a tr- 
end towards a longer re- 
currence-free and overall 
survival was surely seen 
in TAN- MCCs. 
Interestingly however, the 
presence of TLS in pri- 
may MCCs significantly 
correlated with recurre- 
nce-free survival (TLS+ vs. 
TLS-: median 40 vs. 3 
months, P=0.025; Table 
3; Figure 2A). Patients 
with MCCs containing TLS 
also had a somewhat lo- 
nger overall survival th- 
an those with TLS- tumors 
(median 29 vs. 18 mon- 
ths), but differences were 
not statistically significant 
(P=0.651; Table 3). In 
addition, TLS were signifi-
cantly associated with a 
higher CD8/CD4 ratio in 
the tumor periphery (P= 
0.032), but not in the 
center of the tumor (P > 
0.999). Clinicopathologic- 
al characteristics such as 
age, gender and stage at 
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tumoral macrophages and peritumoral immune 
cells was associated with specific clinicopatho-
logical characteristics or survival of our cohort. 
Eight of 19 primary MCCs (2 not assessed, no 
more tissue available) were strongly positive for 
PD-L1 (for exemplary immunohistochemical 
stainings of PD-L1 positive and PD-L1 negative 
MCCs see Figure 3A, 3B). In addition, 8 of 19 
MCCs showed a strong infiltration with PD-L1 
positive macrophages and 7 of 19 MCCs had 
peritumoral PD-L1 positive immune cells (Table 
4, for exemplary immunohistochemichal stain-
ings of PD-L1 positive macrophages and PD-L1 
positive immune cells see Figure 3C, 3D). Nei- 
ther sex nor age nor stage at initial diagnosis 
significantly correlated with PD-L1 expression 
in tumor cells and immune cells (Table 4). In 
addition, PD-L1 positivity in tumor cells or im- 
mune cells did not impact the frequency of 
local recurrence, recurrence-free or overall sur-
vival in our cohort (Table 4).
Taken together, the presence of TLS was the 
only histopathological finding associated with 
prolonged recurrence-free survival in our pa- 
tient cohort.
Discussion
Our study shows for the first time that presence 
of TLS in the tumor periphery of MCCs signifi-
cantly correlates with prolonged recurrence-
free survival and that this is associated with a 
higher CD8/CD4 ratio in the tumor periphery. 
The immune system plays a central role for sys-
temic tumor surveillance; accordingly, immuno-
suppressed patients bear a considerably high-
er risk of developing malignancies, including 
MCCs [1]. In addition, data from diverse studies 
support an association of a robust T-cell infiltra-
tion in the tumor with a better prognosis in 
malignancies such as colorectal, breast and 
ovarian carcinoma [32-35]. In MCC presence of 
Figure 3. Exemplary immunostainings of primary MCC classified as PD-L1 positive (A) or negative (B), PD-L1 positive 
intratumoral macrophages (C) and PD-L1 positive peritumoral inflammatory infiltrate (D). Scale bar: 100 μm.
Tertiary lymphoid structures and immune cell infiltration in Merkel cell carcinomas
7617 Int J Clin Exp Pathol 2014;7(11):7610-7621
Table 4. Relationship of PD-L1-expression in tumor cells, immune cells with clinicopathological features and survival rates  
Tumor
PD-L1+ intratumoral  
macrophages Immune Cells (peritumoral)
PD-L1+ PD-L1- P PD-L1+ PD-L1- P PD-L1+ PD-L1- P
n 8 11 8 11 7 12
Age (y), mean (SD) 73.1 (13.2) 71.3 (11.5) 0.71* 67.6 (11.4) 75.3 (11.8) 0.14* 72.6 (11.3) 73.5 (12.8) 0.83*
Sex, n (%)
    Female 5 (62.5) 4 (36.4) 0.37 4 (50) 5 (45.5) > 0.99 4 (57.1) 5 (41.7) 0.65
    Male 3 (37.5) 7 (63.6) 4 (50) 6 (54.5) 3 (42.9) 7 (58.3)
Stage at initial diagnosis, n (%)
    I/II 7 (87.5) 6 (54.5) 0.10† 6 (75) 7 (63.9) > 0.99† 6 (85.7) 7 (58.3) 0.6†
    III/IV 0 (0) 5 (45.5) 2 (25) 3 (27.3) 1 (14.3) 4 (33.3)
    Unknown 1 (12.5) 0 (0) 0 (0) 1 (9.1) 0 (0) 1 (8.3)
Local recurrence, n (%)
    Yes 2 (25) 3 (27.3) > 0.99† 1 (12.5) 4 (36.4) 0.12† 1 (14.3) 4 (33.3) 0.58†
    No 4 (50 6 (54.5) 7 (87.5) 3 (27.3) 5 (71.4) 5 (41.7)
    Unknown 2 (25) 2 (18.2) 0 (0) 4 (36.4) 1 (14.3) 3 (25)
Recurrence-free survival (n=14)
    Median (IQR 25; 75) 17.0 (2; 54) 3 (1.5; 49.5) 0.79*  19 (0; 59) 3.0 (3; 51) 0.8*  19 (1.5; 49.5) 3 (2; 54) 0.84*
    Min-Max 1-57 0-105 0-105 1-57 0-59 0-105
Overall survival (n=16)
    Median (IQR 25; 75) 54.5 (13.3; 66.8) 18.5 (5; 70.5) 0.75* 29.5 (7.5; 57.3) 37 (5.5; 84.3) 0.75* 18.5 (4.3; 44.8) 54.5 (6.5; 96) 0.30*
    Min-Max 2-93 4-135 2-105 5-135 2-59 4-135
SD: standard deviation; *Mann-Whitney-U-Test; †Fisher’s Exact Test.
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a dense CD3+ and CD8+ T-cell infiltrate is a 
favorable prognostic sign [10, 11, 29]. The fact 
that we did not find any significant correlation 
of recurrence-free or overall survival with intra- 
and peritumoral CD8+ or CD3+ T-cells may be 
do to the small sample size of our cohort.
Intratumoral T- and B-cells can specifically rec-
ognize tumor antigens [36, 37], which has also 
been shown for CD8+ and CD4+ T-cells in MCCs 
[38]. However, little is known about the mecha-
nisms controlling such a specific immune acti-
vation. Generally it is believed that secondary 
lymphoid structures such as draining lymph 
nodes are the major sites of lymphocyte activa-
tion. Recently, however, TLS have been identi-
fied in direct tumor proximity. The presence of 
such structures has been associated with a 
better prognosis in diverse tumor entities such 
as colon, lung, breast and renal carcinomas as 
well as in melanomas [31, 39-42]. TLS are com-
posed of T- and B-cell areas. In B-cell areas fol-
licular dendritic cells and B-cells are found, 
while in T-cell areas high endothelial venules, 
mature dendritic cells as well as T-cells are 
localized in close proximity [31]. Such a cluster-
ing of antigen-presenting cells with cells of the 
adaptive immune system is thought to facilitate 
the development of a specific anti-tumor im- 
mune response by bringing the whole immune 
cell repertoire in close proximity to tumor anti-
gens. In our study TLS were analyzed for the 
first time in MCCs. More than one third of the 
MCC samples studied contained such struc-
tures (8 of 21). Interestingly, the TLS status sig-
nificantly correlated with the CD8/CD4 ratio in 
the tumor periphery. It has been reported that 
the presence of TLS mature dendritic cells is 
specifically associated with a Th1 and CD8+ 
cytotoxic T-cell response in non small cell lung 
carcinoma patients and that this finding corre-
lates with improved long-term survival [43]. 
Based on our analysis we cannot conclude that 
the association of a higher CD8/CD4 ratio in 
the tumor periphery with the presence of TLS is 
a sign of a specific immune-mediated anti-
tumor response. To confirm this hypothesis, it 
will be necessary to study the T-cell receptor 
repertoire and T-cell activation status. Inte- 
restingly, also all local recurrences and distant 
metastases studied in this work contained TLS. 
The presence of TLS in metastases has already 
been described for melanoma [31]. The authors 
suggested that TLS might be a sign of an active 
immune reaction against neoplastic cells. Ba- 
sed on their results they could not say whether 
the presence of TLS helps or impairs tumor pro-
gression as TLS can also be involved in the 
induction of peripheral immune tolerance [31, 
44]. Clearly, the association between TLS and 
recurrence-free survival of MCC patients docu-
mented here as well as the impact of TLS on 
metastasis formation and overall survival need 
to be verified in larger patient cohorts.
Patients with MCC have a high risk of lymph 
node and distant metastasis in the course of 
their disease [45]. Although their tumors are 
usually chemosensitive with overall response 
rates of 60-70% [46, 47], the median duration 
of response to currently used chemotherapy 
regimens is only about 8 months [45]. Therefore 
new therapeutic options are urgently needed. 
The promotion of an anti-tumor-directed im- 
mune response by blockade of inhibitory co-
stimulatory receptors or ligands such as CTLA-
4, PD-1 and PD-L1 has proven effective for 
patients with advanced melanoma and other 
cancers [21, 22, 48]. Tumor cells express PD- 
L1 especially in response to inflammatory stim-
uli as a sign of immune resistance [49]. It has 
been suggested that surface expression of PD- 
L1 on tumor cells might be a useful biomarker 
to identify patients who benefit from therapeu-
tic PD-1 and PD-L1 blockade [50]. Surface ex- 
pression of PD-L1 has been reported in about 
50% of MCCs [24]. Interestingly, PD-L1 expres-
sion in MCCs has been identified as a favorable 
prognostic marker [22]. It has been postulated 
that strong PD-L1 expression in tumor cells 
could point to a strong immune response ag- 
ainst MCCs mediated by IFN-gamma secreting 
CD8+ lymphocytes [24], which leads to up-reg-
ulation of PD-L1 in tumor cells in an attempt to 
reestablish a permissive environment. In our 
study we were able to confirm the PD-L1 sur-
face expression on 42% of the primary MCCs. 
However, we did not find any correlation with 
patients’ survival rates, possibly due to the 
small sample size. Clearly, the prognostic value 
of PD-L1 in MCC needs to be further assessed. 
However, based on our results and the findings 
by Lipson and colleagues we believe that in 
patients with advanced MCCs checkpoint blo- 
cking agents such as anti-PD-1 or anti-PD-L1 
might be promising therapeutic options.
In summary, we were able to confirm surface 
expression of PD-L1 in a significant proportion 
of MCCs. In addition, we identified TLS as po- 
tentially novel prognostic markers, which are 
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easy to assess in paraffin-embedded tissue. 
Validation of these findings in larger patient co- 
horts and tumor samples and exploration of 
these molecules as tools for routine diagnostic 
or targets for novel therapies will be of great 
interest.
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Figure S1. Exemplary immunohistochemical stainings of MCCs for (A) CD3, (B) CD4, (C) CD8, (D) PD-1, (E) CD31, 
(F) Ki67.
Table S1. Immune cell infiltration in MCCs
Mean (SD) Median (IQR 25, 75) Min-Max
CD3 [cells/mm2] 135 (393) 16 (6, 72) 0-1764
CD4 [cells/mm2] 135 (482) 18 (0, 53) 0-2175
CD8 [cells/mm2] 172 (302) 25 (6, 253) 0-1188
CD68 [cells/mm2] 182 (121) 137 (109, 232) 16-534
CD31 [cells/mm2] 47 (55) 29 (25, 45) 18-278
Ki67 [%] 14 (10) 13 (5, 20) 3-30
